Patent ID: 8512745

Claim:
A pharmaceutical tablet for oral administration comprising: 3 to 18 wt % of ulipristal acetate, wherein ulipristal acetate is present in the tablet in an amount ranging from 5 mg to 50 mg, 60 to 95 wt % of a diluent selected from the group consisting, of lactose monohydrate and mannitol, 1 to 10 wt % of a binding agent selected from the group consisting of hydroxypropyl methyl cellulose and povidone, 1 to 10 wt % of croscarmellose sodium, and 0 to 5 wt % magnesium stearate, wherein the tablet is an oral tablet and is uncoated, and wherein at least about 90% (w/w) of ulipristal acetate present in the tablet is dissolved within about 20 minutes when the tablet is subjected to an in vitro dissolution assay according to the general monograph of the European Pharmacopoeia §2.9.3, at 37°C.±0.5°C., a rotation speed of 50 rpm and pH=1.